The National Institute for Health and Care Research (NIHR) is pleased to share an opportunity to be involved in shaping a commercial research study in small cell lung cancer. The NIHR wants to hear your experiences of living with, or supporting others with, this condition to ensure that this and future research is as accessible as possible for everyone, by designing it for patients, with patients.

This activity involves carrying out an online document review where you will be asked to comment upon the design of a research study and feed back on how the information introducing the research is presented to patients. We want to ensure that the documents are informative, accessible, engaging and fit for purpose, and that the language used is appropriate for potential participants and carers.

They are looking for:

For this opportunity, the NIHR is looking for up to 6 adult individuals (aged 18 or over), living in the UK, who meet the following criteria:

  • Have been diagnosed with small cell lung cancer

And either:

  • Are in the extensive stage (meaning the cancer is in more than one, single area of the lung); and
  • Have not received any systemic therapy (treatments that work throughout the whole body such as chemotherapy, immunotherapy, hormonal treatment or targeted therapies such as monoclonal antibodies) since the cancer has been in the extensive stage

Or:

  • Have received platinum-based chemotherapy (such as cisplatin, carboplatin or oxaliplatin) but the cancer has progressed or returned

This activity will be most relevant to people who meet all of the criteria in the above categories, but they would still be happy to hear from you even if you do not match them all.

They would also encourage people with experience of caring for someone who has had this condition to put themselves forward.

You will need to be comfortable with reviewing the documentation and sending back comments online and be willing to discuss your experiences and management of this condition.

Prescribing clinicians are not permitted to participate for regulatory reasons. If you are a prescribing clinician and are unsure about your eligibility, please get in touch with the NIHR team to discuss this.

Expected commitment from participants:

They anticipate that it would take you up to 2 hours to read the documents and fill in the feedback form. Contributors will have 10-days to complete the review and return, but the team sensitive to availability.

Commitment to inclusion:

Documents will be sent via email. The NIHR team will endeavour to make these documents as accessible as possible, depending on participant requirements.

Closing date to apply: 15th April 2023

If the NIHR receives a large number of expressions of interest, they may need to close this opportunity to recruitment sooner than planned. So we would encourage anyone who might like to take part to complete the form as soon as possible.

 

The post Opportunity to review study documentation for a trial into lung cancer appeared first on Shaping Our Lives.